Trial · NCT02576717
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Parent Treatment Group IFN-B-1a 30 ug | 740 | |
| Overall Study | STARTED | Parent Treatment Group: RPC1063 0.5 mg | 875 | |
| Overall Study | STARTED | Parent Treatment Group: RPC1063 1.0 mg | 879 | |
| Overall Study | Transferred From IFN β-1a Parent Group | Parent Treatment Group IFN-B-1a 30 ug | 0 | |
| Overall Study | Transferred From IFN β-1a Parent Group | Parent Treatment Group: RPC1063 0.5 mg | 3 | |
| Overall Study | Transferred From IFN β-1a Parent Group | Parent Treatment Group: RPC1063 1.0 mg | 1 | |
| Overall Study | Transferred From RPC1063 0.5 mg Parent Group | Parent Treatment Group IFN-B-1a 30 ug | 0 | |
| Overall Study | Transferred From RPC1063 0.5 mg Parent Group | Parent Treatment Group: RPC1063 0.5 mg | 0 | |
| Overall Study | Transferred From RPC1063 0.5 mg Parent Group | Parent Treatment Group: RPC1063 1.0 mg | 1 | |
| Overall Study | Randomized to Placebo in the Parent Study | Parent Treatment Group IFN-B-1a 30 ug | 0 | |
| Overall Study | Randomized to Placebo in the Parent Study | Parent Treatment Group: RPC1063 0.5 mg | 37 | |
| Overall Study | Randomized to Placebo in the Parent Study | Parent Treatment Group: RPC1063 1.0 mg | 35 | |
| Overall Study | Safety Population | Parent Treatment Group IFN-B-1a 30 ug | 736 | |
| Overall Study | Safety Population | Parent Treatment Group: RPC1063 0.5 mg | 877 | |
| Overall Study | Safety Population | Parent Treatment Group: RPC1063 1.0 mg | 881 | |
| Overall Study | COMPLETED | Parent Treatment Group IFN-B-1a 30 ug | 564 | |
| Overall Study | COMPLETED | Parent Treatment Group: RPC1063 0.5 mg | 691 | |
| Overall Study | COMPLETED | Parent Treatment Group: RPC1063 1.0 mg | 695 | |
| Overall Study | NOT COMPLETED | Parent Treatment Group IFN-B-1a 30 ug | 176 | |
| Overall Study | NOT COMPLETED | Parent Treatment Group: RPC1063 0.5 mg | 184 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02576717/flow